Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar bouhassi (< 20) Submitted: 6/10/2007 10:57:36 PM : Outperform Start Price: $10.26 HALO Score: -11.54

great technology

Featured Broker Partners


Advertisement